Delivery Order SPE2DB22D3009-SPE2DB25FBD73
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Creon DR 24,000 unit capsules (100 count) with a ceiling value of $2,262.52 and an ultimate completion date of August 11, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical...
- The Defense Logistics Agency awarded a $2,376.88 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of 36,000 unit capsules of Creon 100s, a pancreatic enzyme replacement therapy. This competitively awarded, firm fixed-price delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of 24,000 unit capsules of Creon DR 100s, with a ceiling value of $8,755.73 and a firm fixed price structure. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order is scheduled for completion by August...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of 36,000 units of Creon DR 100s capsules, with a ceiling value of $11,594.70. This competitive award, issued with firm fixed-price pricing and no set-aside designation, is fulfilled from the company's place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 13, 2025. This delivery order is a child contract under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Creon DR 36,000 unit capsules in quantities of 100 units. This non-set-aside, firm fixed-price delivery order has a ceiling value of $6,733.40 and is scheduled for ultimate completion by August 19, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $1,725.36 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for 36,000 unit capsules of Creon DR 100s, with an ultimate completion date of August 8, 2025. The contract was competitively awarded with no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count packaging, valued at $2,254.12. This is a firm fixed-price delivery order with no set-aside designation, issued under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive $999.99 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a delivery order valued at $4,499.56 to AmerisourceBergen Drug Corp for 36,000 units of Creon DR 100s capsules, with an ultimate completion date of September 2, 2025. This non-set-aside contract utilizes firm fixed pricing and represents a delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $9,025.18 to AmerisourceBergen Drug Corp for 36,000 unit capsules of Creon (pancreatic enzyme replacement therapy) in 100-count bottles. This firm fixed price delivery order, issued on August 11, 2025, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $7,093.80 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for 36,000 units of Creon DR 100-strength capsules, with an ultimate completion date of August 29, 2025. This competitively awarded, non-set-aside contract represents a single delivery order for pharmaceutical supplies to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger...
- SPE2DB22D3009Indefinite Delivery Contract
- SPE2DB22D3009-SPE2DB25FBD73Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Creon DR 36,000 unit capsules in 100-count packages, with a contract value of $3,339.59 and completion date of August 22, 2025. This non-set-aside, firm fixed-price delivery order represents a competitive award supporting federal pharmaceutical procurement needs. The award is issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical supply vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills a critical role in the federal medical supply chain through its extensive portfolio of brand-name and generic medications, vaccines, and medical supplies. The company's federal contract awards consistently demonstrate its capability to meet diverse pharmaceutical needs across multiple therapeutic domains and customer bases, including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order for Creon, a pancreatic enzyme replacement therapy, exemplifies the company's ongoing support of military healthcare logistics and pharmaceutical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 8/21/25 |